RxDoctor Payments Data

Hari Bodhireddy, MD

Ophthalmology · Spokane, WANPI 1932423605

Payments from drug & device makers

$2,327in general payments, 2019–2025

Across 68 payments — averaging $34.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$667
  • Alcon$614
  • AbbVie$494
  • Aerie Pharmaceuticals, Inc.$250
  • Glaukos Corporation$200
  • Eyepoint US, Inc.$24
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$1,66071%
  • Ownership interest$66729%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,327 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$394,353
Medicare patients
637
Services billed
2,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate215$94,828
LumiganBimatoprost112$51,247
RocklatanNetarsudil Mesylat/Latanoprost55$29,285
CombiganBrimonidine Tartrate/Timolol64$23,085
Alphagan PBrimonidine Tartrate38$16,270
Prednisolone Acetate473$16,197
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol82$14,421
Latanoprost973$12,983
Dorzolamide-TimololDorzolamide/Timolol/Pf76$12,003
TafluprostTafluprost/Pf55$11,815
Fluorometholone124$11,532
Brimonidine Tartrate262$9,381
Ketorolac Tromethamine445$9,333
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat527$8,874
TyrvayaVarenicline Tartrate12$8,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$250$124,114270 claims
AbbVieLumigan, Combigan, Alphagan P$494$90,602214 claims
AlconSimbrinza, Azopt$614$12,67037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →